Answers are grounded in this paper and cite their sources.
Hepatosplenic schistosomiasis affects about 4–8% of individuals with schistosomal infection. Upper gastrointestinal bleeding (UGB) is the most common complication of schistosomiasis-induced liver fibrosis. This study aimed to compare the efficacy and safety of transjugular intrahepatic portosystemic shunt (TIPS) versus endoscopic therapy combined with nonselective beta-blockers (EC-NSBBs) for secondary prevention of schistosomiasis-related variceal bleeding. We retrospectively analyzed 67 patients with schistosomal liver disease and a history of gastroesophageal variceal bleeding. 37 patients underwent TIPS creation, while 30 patients received endoscopic therapy combined with NSBBs. The rates of variceal rebleeding, overt hepatic encephalopathy (OHE), and survival were compared between the two groups. The cumulative probability of variceal rebleeding was significantly lower in the TIPS group compared to the EC-NSBBs group (HR = 0.09, 95% CI: 0.03–0.31, Log-rank P < 0.01), with no significant differences between the two groups in terms of OHE ( P = 0.38) and survival rates ( P = 0.94). In the TIPS group, portal vein thrombosis, ascites, and pleural effusion gradually decreased after 6 months. Multivariate Cox analysis identified treatment modality, CTP score, and variceal diameter as predictors of variceal rebleeding. TIPS significantly reduces the rebleeding rate in patients with schistosomiasis-related varices with a favorable safety profile.
No takes yet. Share an insight, caveat, or question.
Lei et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: